Foveal LLP Independent Investment Research Foveal Research

Vaxcyte’s pivotal OPUS-1 readout by the end of October is not a simple 31/31 pass/fail event. Management has already framed several expected serotype misses, so the stock debate is whether VAX-31 can deliver a meaningfully better-than-guided profile versus merely protecting adult value already embedded in PCVX’s valuation. Our latest report focuses on where the readout could surprise positively or negatively, how likely those outcomes are, how much they matter commercially, a

Pelacarsen’s HORIZON failure materially raises the burden of proof for the Lp(a) class, but we think the investment question for Amgen now shifts from the headline failure to whether the eventual dataset supports a class-wide read-through or leaves room for olpasiran differentiation. Our latest work frames the key clinical and trial-design debates that will determine how much of the HORIZON outcome should be reflected in Amgen’s risk–reward ahead of OCEAN(a), and where curren